MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Gesloten

SectorGezondheidszorg

3.59 6.21

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.31

Max

3.63

Belangrijke statistieken

By Trading Economics

Inkomsten

-15M

-40M

Verkoop

8.2M

50M

Winstmarge

-80.43

Werknemers

435

EBITDA

-19M

-42M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+17.99% upside

Dividenden

By Dow Jones

Volgende Winsten

11 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

4.2M

1.1B

Vorige openingsprijs

-2.62

Vorige sluitingsprijs

3.59

Nieuwssentiment

By Acuity

50%

50%

159 / 348 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

20 apr 2026, 23:49 UTC

Belangrijke Nieuwsgebeurtenissen

New Zealand 1Q Inflation Higher Than Expected

20 apr 2026, 23:10 UTC

Populaire aandelen

Stocks to Watch: Amazon, Alaska Air Group, BridgeBio Oncology, AXT

20 apr 2026, 22:53 UTC

Belangrijke Marktbewegers

BridgeBio Oncology Shares Rise After FDA Fast-Tracks Pancreatic Cancer Treatment

20 apr 2026, 23:45 UTC

Marktinformatie

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

20 apr 2026, 23:44 UTC

Marktinformatie

Gold Consolidates as End of Cease-Fire Looms -- Market Talk

20 apr 2026, 23:39 UTC

Marktinformatie

Rio Tinto Posts Strong Start to Year -- Market Talk

20 apr 2026, 23:30 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

20 apr 2026, 23:30 UTC

Marktinformatie

Global Equities Roundup: Market Talk

20 apr 2026, 23:30 UTC

Marktinformatie

Super Retail's Earnings Outlook Less Rosy -- Market Talk

20 apr 2026, 23:09 UTC

Marktinformatie

Viva Energy's Refinery Fire More Benign Than Jefferies Thought -- Market Talk

20 apr 2026, 22:31 UTC

Acquisities, Fusies, Overnames

Anthropic, Amazon Tighten Bond in $5 Billion Investment and Computing Deal -- WSJ

20 apr 2026, 22:26 UTC

Acquisities, Fusies, Overnames

West African Resources Says Sanbrado, Toega Operations Not Subject to Govt Request for Additional Participation

20 apr 2026, 22:25 UTC

Acquisities, Fusies, Overnames

West African Resources Plans to Distribute Cash Proceeds to Shareholders Via Special Dividend

20 apr 2026, 22:25 UTC

Acquisities, Fusies, Overnames

West African Resources Aims for Acquisition to Be Completed by End-2026

20 apr 2026, 22:25 UTC

Acquisities, Fusies, Overnames

West African Resources Says to Work Cooperatively With Govt to Finalize Deal Terms

20 apr 2026, 22:25 UTC

Acquisities, Fusies, Overnames

West African Resources Says Acquisition Would Be for A$175 Million

20 apr 2026, 22:24 UTC

Acquisities, Fusies, Overnames

West African Resources Says Burkina Faso Govt Issues Decree to Acquire 25% of Kiaka

20 apr 2026, 22:15 UTC

Acquisities, Fusies, Overnames

Anthropic, Amazon Tighten Bond in $5 Billion Investment and Computing Deal -- WSJ

20 apr 2026, 22:01 UTC

Acquisities, Fusies, Overnames

Amazon Invests $5B in Anthropic Amid Expanded Collaboration

20 apr 2026, 21:38 UTC

Marktinformatie

Apple's New CEO Will Face Immediate Pressure on AI Strategy -- Market Talk

20 apr 2026, 21:33 UTC

Acquisities, Fusies, Overnames

Uber Expands Stake In Lucid for Robo-Taxis. This Is How Tesla's Stock Is Responding. -- Barrons.com

20 apr 2026, 21:24 UTC

Marktinformatie

Apple's CEO Change Timing Will Garner Mixed Reaction, Analyst Says -- Market Talk

20 apr 2026, 21:24 UTC

Marktinformatie

Global Equities Roundup: Market Talk

20 apr 2026, 21:13 UTC

Winsten

Alaska Air: Expansion of Card Portfolio Expected to Accelerate Loyalty Platform Beyond Incremental $150M Profit Outlined in Alaska Accelerate Strategy

20 apr 2026, 21:10 UTC

Winsten

Alaska Air to Move Toward a Single Issuer for Atmos Rewards Credit Cards

20 apr 2026, 21:09 UTC

Winsten

Alaska Air Sees 2Q Capacity Up About 1% Year-Over-Year, Down Nearly a Point From Original Views, on 'Proactive Trimming' of May and June Capacity

20 apr 2026, 21:08 UTC

Winsten

Alaska Air 'Continues to Operate From a Position of Strength,' With Healthy Balance Sheet, Strong Liquidity, About $20B in Unencumbered Assets

20 apr 2026, 21:07 UTC

Winsten

Alaska Air: Taken Together, Rev, Cost and Fuel Assumptions Result in 2Q Adjusted Loss Per Share Estimate of About $1

20 apr 2026, 21:05 UTC

Winsten

Alaska Air: This Assumption Adds About $600M of Expense to 2Q, Equivalent to EPS Headwind of $3.60

20 apr 2026, 21:05 UTC

Winsten

Alaska Air Expects 2Q Fuel Cost to Average About $4.50 Based on Forward Curve Today

Peer Vergelijking

Prijswijziging

Maravai LifeSciences Holdings Inc (Class A) Prognose

Koersdoel

By TipRanks

17.99% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4 USD  17.99%

Hoogste 5 USD

Laagste 3 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Maravai LifeSciences Holdings Inc (Class A) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

3

Buy

3

Hold

0

Sell

Technische score

By Trading Central

2.02 / 2.115Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

No Evidence

Sentiment

By Acuity

159 / 348 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat